Real-life use of onabotulinumtoxinA reduces healthcare resource utilization in individuals with chronic migraine: the REPOSE study

Table 1 Baseline demographic and migraine characteristics of patients in the REPOSE study (overall and German populations)

	Overall Population^a (n = 633)	German Population^b (n = 377)
Mean (SD) age, years	45.4 (11.7)	46.3 (11.8)
Female, n (%)	540 (85.3)	318 (84.4)
Mean (SD) monthly headache days	20.6 (5.4)	18.9 (4.5)

^aPercentages are based on total number of patients who received ≥1 dosage of onabotulinumtoxinA
^bPercentages are based on the total number of patients treated at German study centres who received ≥1 dosage of onabotulinumtoxinA

ISSN: 1129-2377